metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
mHCC - 1st line (L1) metastatic/advanced hepatocellular cancer (mHCC) mHCC - 1st line (L1)
versus sorafenib
	bevacizumab
	ORIENT-32, 2021 NCT03794440	RCT	mHCC - 1st line (L1)	Sintilimab plus IBI305 (bevaciumab biosimilar)	Sorafenib	patients with unresectable, locally advanced, or metastatic hepato cellular carcinoma, with a diagnosis that was histologically, cytologically, or clinically confirmed, who had received no previous systemic therapy for advanced or metastatic disease, or were unsuitable for radical surgery or had local treatment stage B	380 / 191	low	conclusif	demonstrated 43 % decrease in deaths (OS) (PE)
	VEGF(R) inhibitor
	CARES-310, 2023 Lancet 2023; 402:1133-1146-. NCT03764293	RCT	mHCC - 1st line (L1)	camrelizumab and rivoceranib (=apatinib)	sorafenib	adult with confirmed hepatocellular carcinoma; had Barcelona Clinic Liver Cancer stage B or C disease, which was not amenable to or had progressed after surgical or locoregional therapy; and had not previously received any systemic therapy	272 / 271	NA	conclusif	demonstrated 38 % decrease in deaths (OS) (PE) demonstrated 48 % decrease in progression or deaths (PFS) (PE) suggested 46 % decrease in PFS (extension)